Galaxy Surfactants Ltd

Dematerialisation processing and certificate status

• Dematerialisation requests processed by the Registrar and Transfer Agent and confirmed to depositories.
• Securities dematerialised listed on stock exchanges where the existing securities are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled after verification; depository name substituted in records within timelines.

Purpose

• Purpose: Seek Members’ consent for two ordinary resolutions—subsidiary appointment and director appointment.

Resolutions

• Resolution 1 (Ordinary): Approve Namrata Natarajan’s 3-year appointment at Galaxy Surfactants Americas, Inc (subsidiary) from Aug 24, 2026.
• Resolution 2 (Ordinary): Appoint Uday K. Kamat as Non-Executive, Non-Independent Director effective Oct 5, 2026.

Outcomes

• Outcome: Not disclosed in notice.

Galaxy Surfactants Limited trading window closed from Oct 01, 2026 until the end of 48 hours after the declaration of financial results for the quarter and half year ended Sep 30, 2026

Meeting Details

• Date & Time: 21 September 2026, 2:00 pm to 5:00 pm
• Nature of Meeting: Investor Conference
• Organised by: Anand Rathi Conference
• Mode: In-person

Participants

• Company officials to attend; specific management roles not disclosed

Purpose

• Discussions based on publicly available information

Additional Notes

• No UPSI intended to be discussed during interactions

Meeting Details

• 8 Sep 2026, 9:00–17:00, Non-Deal Roadshow, in-person, Mumbai, hosted by Nuvama IE.
• 10 Sep 2026, 9:00–17:00, 1x1 / Group Meeting, in-person, Mumbai.

Participants

• Key company participants: management officials and the Company Secretary.

Purpose

• Purpose: investor discussions based on public information; no UPSI intended.

Additional Notes

• Changes may occur due to host or company exigencies.

Meeting Details

• Date and time: 2 September 2026, 2:00 pm–5:00 pm.
• Nature: Investor Conference; mode: In-person.
• Organiser: Elara Capital Conference.

Participants

• Company officials to attend the investor conference.

Purpose

• Discussions based on publicly available information; no UPSI discussed.

Financial Performance

• Q1 FY27 EBITDA: INR 252.5 crores vs INR 135.1 crores in Q1 FY26.
• EBITDA per MT: INR 35,458 vs INR 20,009 YoY.
• Consolidated volumes up 5% YoY; India +11%; AMET down 4% YoY, +19% sequential.
• Rest of World volumes up 6% YoY; APAC double-digit growth.
• Mexico EPC project on track; commercialization in 12 months.
• SimpliX launched; Galaxy Hearth Biosurf wins Innovation Zone Award 2026.

Regional Trends

• India grew 11% led by performance segment; Tier 1 demand recovering.
• Oleochemical feedstock advantage; reformulation favorable; premiumization gains.
• AMET volumes down 4% YoY but +19% sequential; Egypt recovery steady.
• APAC and Americas driving growth; TRI-K strength supporting mix.
• West Asia volatility ongoing; supply continuity remains priority.

Guidance and Outlook

• Volume guidance retained at 6%–8% for FY26-27.
• EBITDA per MT guidance raised to INR 24,000–25,000.
• EPC income recognition this quarter; complete by year-end; impact not material.
• Capex guidance about INR 150–200 crores for the year; front-loaded.
• Demand indicators remain encouraging; festive season momentum; West Asia developments watched.

Q&A Highlights

• Q1: 35k EBITDA/MT driven by reformulation and mix; sustainable range ~21–22k; long-term 24–25k.
• Q2: US demand momentum; Everbond launch; guidance intact.
• Q3: BASF Dahej closure could lift demand; not quantified yet.
• Q4: EPC income timing; to be fully recognized by year-end; in a separate segment.
• Q5: Capex around INR 150 crores; no AMET acquisitions; debottlenecking planned.

Partnership with Unilever

• Galaxy Surfactants signed a Partnership Growth Charter with Unilever to accelerate new chemistries and next-generation surfactants.
• Aims include supply resilience, bio-based and lower-carbon technologies, and value-chain collaboration.
• Builds on Galaxy-Unilever 45-year relationship to expand collaboration.

Filing Status

• No substantive transcript body present; wrapper-only filing with audio recording.

Financial performance

• Total revenue for Q1FY27 was ₹1,785.2 crore, up 38.5% YoY and 35.8% QoQ.
• Highest-ever quarterly EBITDA recorded at ₹252.5 crore; EBITDA margin 14.1%.
• PAT stood at ₹165.9 crore; PAT margin 9.3%.
• EBITDA per MT ₹35,458, up from ₹20,009 YoY.
• Consolidated revenue mix: Performance Surfactant ₹1,178.7 crore; Specialty Care ₹603.2 crore.
• India region delivered double-digit volume growth; AMET shows sequential improvement.